All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with ...
- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in a poster session at the American Society of Clinical ...
AEMD CMO will present data on Hemopurifier potential in Long Covid at Keystone Symposium We met virtually with medical therapeutic company Aethlon Medical (NASDAQ:AEMD) this week and present our ...
SAN DIEGO--(BUSINESS WIRE)--Lassen Therapeutics, a clinical stage biotech company developing first-in-class antibody therapeutics targeting interleukin-11 receptor (IL-11R) and interleukin-18 binding ...
MUMBAI, India and NAPLES, Fla. and BERLIN, Oct. 13, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) will present data ...
The regional agency asked for the research to be undertaken aas the prospect of local projects have become a hot button issue.
Molecular Partners (MOLN) and Orano Med announced the oral presentation of the latest preclinical data supporting MP0712 as a Radio-DARPin Therapeutic, or RDT, at the European Assocation of Nuclear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback